212 related articles for article (PubMed ID: 37469246)
21. Incorporation of the SUVmax Measured From FDG PET and Neutrophil-to-lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients With Locally Advanced Non-small-cell Lung Cancer.
Guo D; Jin F; Jing W; Li M; Chen D; Zou B; Jiang G; Fu L; Zhu H; Kong L; Wu J; Yu J; Yue J
Clin Lung Cancer; 2019 Nov; 20(6):412-419. PubMed ID: 31300364
[TBL] [Abstract][Full Text] [Related]
22. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
23. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Yao Y; Yuan D; Liu H; Gu X; Song Y
Cancer Immunol Immunother; 2013 Mar; 62(3):471-9. PubMed ID: 22986452
[TBL] [Abstract][Full Text] [Related]
24. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy.
Berardi R; Rinaldi S; Santoni M; Newsom-Davis T; Tiberi M; Morgese F; Caramanti M; Savini A; Ferrini C; Torniai M; Fiordoliva I; Bower M; Cascinu S
Oncotarget; 2016 May; 7(18):26916-24. PubMed ID: 27029035
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Model of Baseline Medications plus Neutrophil-to-lymphocyte Ratio in Patients with Advanced Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitor plus Platinum Doublet: A Multicenter Retrospective Study.
Nasu I; Kondo M; Uozumi R; Takada S; Nawata S; Iihara H; Okumura Y; Takemoto M; Mino K; Sasaki T; Hirose C; Aomori T; Shimano R; Maeno K; Oizumi S; Kusumoto S; Ohno Y; Ikemura S; Takai D; Hara A; Kawazoe H; Nakamura T
J Cancer; 2023; 14(5):676-688. PubMed ID: 37056385
[No Abstract] [Full Text] [Related]
26. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
Garassino MC; Gadgeel S; Speranza G; Felip E; Esteban E; Dómine M; Hochmair MJ; Powell SF; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Kurata T; Gray JE; Schwarzenberger P; Jensen E; Pietanza MC; Rodríguez-Abreu D
J Clin Oncol; 2023 Apr; 41(11):1992-1998. PubMed ID: 36809080
[No Abstract] [Full Text] [Related]
27. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].
Dong X; Zhou ZM; Bi N; Wang JB; Ran JT; Hui ZG; Liang J; Feng QF; Chen DF; Xiao ZF; Lyu JM; Wang XZ; Wang X; Zhang T; Deng L; Wang WQ; Wang LH
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):446-451. PubMed ID: 29936771
[No Abstract] [Full Text] [Related]
28. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
29. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.
Wasamoto S; Imai H; Tsuda T; Nagai Y; Minemura H; Yamada Y; Umeda Y; Kishikawa T; Shiono A; Kozu Y; Shiihara J; Yamaguchi O; Mouri A; Kaira K; Kanazawa K; Taniguchi H; Kaburagi T; Minato K; Kagamu H
Front Oncol; 2022; 12():1080729. PubMed ID: 36741711
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer: an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial.
Belani CP; Wu YL; Chen YM; Kim JH; Yang SH; Zhang L; Peterson P; Orlando M
J Thorac Oncol; 2012 Mar; 7(3):567-73. PubMed ID: 22157370
[TBL] [Abstract][Full Text] [Related]
32. [Peripheral Blood Inflammation Indicators as Predictive Indicators in
Immunotherapy of Advanced Non-small Cell Lung Cancer].
Xia J; Chen Y; Wen S; Du X; Shen B
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):632-645. PubMed ID: 34521188
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis.
Xiao HQ; Tian RH; Zhang ZH; Du KQ; Ni YM
Onco Targets Ther; 2016; 9():1471-6. PubMed ID: 27042115
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
[TBL] [Abstract][Full Text] [Related]
35. A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.
Wang Z; Zhao J; Ma Z; Cui J; Shu Y; Liu Z; Cheng Y; Leaw SJ; Wu Y; Ma Y; Tan W; Ma X; Zhang Y; Wang J
Lung Cancer; 2020 Sep; 147():259-268. PubMed ID: 32769013
[TBL] [Abstract][Full Text] [Related]
36. High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study.
Sumiyoshi I; Okabe T; Togo S; Takagi H; Motomura H; Ochi Y; Shimada N; Haraguchi M; Shibayama R; Fujimoto Y; Watanabe J; Iwai M; Kadoya K; Iwakami SI; Takahashi K
J Transl Med; 2021 Feb; 19(1):92. PubMed ID: 33639962
[TBL] [Abstract][Full Text] [Related]
37. Clinical observation and prognostic analysis of pemetrexed plus platinum as first-line treatment in patients with advanced non-small cell lung cancer.
Wang JY; Cai Y
Asian Pac J Cancer Prev; 2013; 14(11):6267-71. PubMed ID: 24377516
[TBL] [Abstract][Full Text] [Related]
38. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
39. A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
Wehler T; Thomas M; Schumann C; Bosch-Barrera J; Viñolas Segarra N; Dickgreber NJ; Dalhoff K; Sebastian M; Corral Jaime J; Alonso M; Hynes SM; Lin J; Hurt K; Bence Lin A; Calvo E; Paz-Ares L
Lung Cancer; 2017 Jun; 108():212-216. PubMed ID: 28625637
[TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study.
Zhang J; Wu D; Zhang Z; Long J; Tian G; Wang Y; Ma X; Chen X; Han J; Hu W; Dai L; Nie J; Fang J
Technol Cancer Res Treat; 2021; 20():15330338211039676. PubMed ID: 34821175
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
